alopecia

Posts

Alopecia Treatment Market

Alopecia Treatment Market

Alopecia Treatment Market

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. A sedentary lifestyle and unhealthy diets are leading to loss of hair among masses.

Furthermore, ageing and hormonal imbalance, increasing chronic diseases like arthritis, cancer, hypertension, depression also lead to hair loss, especially among the middle-aged population.

According to the American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men.

Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide.

In recent years, many novel drugs have been approved by the regulatory bodies for the treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in the near future.

Concert Pharmaceuticals Inc. received fast track designation from the United States Food and Drug Administration, (FDA) for its novel product for the treatment of moderate-to-severe alopecia areata in January 2018. The launches of such novel products in the market is expected to drive the global alopecia treatment market growth in the near future.

Key Market Trends

Female is Expected to Hold Largest Share Over the forecast period

About one-third of women experience hair loss (alopecia) at some time in their lives. Among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it’s less socially acceptable for them.

Androgenetic alopecia is the most common cause of hair loss in women. Alopecia can severely affect a woman’s emotional well-being and quality of life.

Although Alopecia is more common in male than female, the female has the largest share in the market owing to the factors such as high awareness levels coupled with increased frequency of Polycystic Ovary Syndrome (PCOS) causing a hormonal imbalance that leads to androgenetic alopecia.

North America Region Holds the Largest Market Share of Alopecia Treatment (Hair Loss) Market

North America dominates the Alopecia Treatment (Hair Loss) market due to the presence of technologically advanced healthcare infrastructure, high disposable income, and availability of novel therapeutics options pertaining to the treatments.

According to the United States National Library of Medicine, Alopecia areata affects 1 in every 500 to 1,000 people in the United States. It is one of many recognized forms of alopecia, alopecia areata is the second most common form after androgenetic alopecia. Alopecia areata affects men and women equally, and it can occur in people of any ethnic background.
Therefore, the high prevalence and the proportionally high treatment rates pertaining to hair loss in the U.S. are high major drivers for the North American market.

Competitive Landscape

Some of the prominent industry players operating in total Alopecia Treatment (Hair Loss) market include Sun Pharmaceuticals Industries Ltd., Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc.

The development of advanced products for better outcomes and rigorous marketing is one of the competitive strategies adopted by the market players. In 2018, HCell Inc., a biotechnology company received orphan drug designation (ODD) for its product from the FDA. Furthermore, in 2017, Perrigo Company PLC. Launched over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Source

Previous Posts

Alopecia Treatment Market

Alopecia Treatment Market

Alopecia Treatment Market

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. A sedentary lifestyle and unhealthy diets are leading to loss of hair among masses.

Furthermore, ageing and hormonal imbalance, increasing chronic diseases like arthritis, cancer, hypertension, depression also lead to hair loss, especially among the middle-aged population.

According to the American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men.

Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide.

In recent years, many novel drugs have been approved by the regulatory bodies for the treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in the near future.

Concert Pharmaceuticals Inc. received fast track designation from the United States Food and Drug Administration, (FDA) for its novel product for the treatment of moderate-to-severe alopecia areata in January 2018. The launches of such novel products in the market is expected to drive the global alopecia treatment market growth in the near future.

Key Market Trends

Female is Expected to Hold Largest Share Over the forecast period

About one-third of women experience hair loss (alopecia) at some time in their lives. Among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it’s less socially acceptable for them.

Androgenetic alopecia is the most common cause of hair loss in women. Alopecia can severely affect a woman’s emotional well-being and quality of life.

Although Alopecia is more common in male than female, the female has the largest share in the market owing to the factors such as high awareness levels coupled with increased frequency of Polycystic Ovary Syndrome (PCOS) causing a hormonal imbalance that leads to androgenetic alopecia.

North America Region Holds the Largest Market Share of Alopecia Treatment (Hair Loss) Market

North America dominates the Alopecia Treatment (Hair Loss) market due to the presence of technologically advanced healthcare infrastructure, high disposable income, and availability of novel therapeutics options pertaining to the treatments.

According to the United States National Library of Medicine, Alopecia areata affects 1 in every 500 to 1,000 people in the United States. It is one of many recognized forms of alopecia, alopecia areata is the second most common form after androgenetic alopecia. Alopecia areata affects men and women equally, and it can occur in people of any ethnic background.
Therefore, the high prevalence and the proportionally high treatment rates pertaining to hair loss in the U.S. are high major drivers for the North American market.

Competitive Landscape

Some of the prominent industry players operating in total Alopecia Treatment (Hair Loss) market include Sun Pharmaceuticals Industries Ltd., Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc.

The development of advanced products for better outcomes and rigorous marketing is one of the competitive strategies adopted by the market players. In 2018, HCell Inc., a biotechnology company received orphan drug designation (ODD) for its product from the FDA. Furthermore, in 2017, Perrigo Company PLC. Launched over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Source

Previous Posts

Alopecia Treatment Market

Global Alopecia Treatment

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

Global Alopecia Treatment (Hair Loss) Market, By Disease Type (Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, Alopecia Totalis), Drug Type (Minoxidil, Finasteride, Cyclosporine and Others), Gender (Male, Female), Route of Administration (Oral, Topical, Injectable), Distribution Channel (Hospital, Retail Pharmacies, Online Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)–Industry Trends & Forecast to 2026

Market Analysis: Global Alopecia Treatment (Hair Loss) Market

The Global Alopecia Treatment (Hair Loss) Market is expected to rise from its initial estimated value of USD 8.21 billion in 2018 to an estimated value of USD 12.40 billion by 2026 registering a CAGR of 5.3% in the forecast period of 2019-2026.

This rise in the market can be attributed to the rising geriatric population along with high demand for surgical hair transplant and changing lifestyle.

Market Definition: Global Alopecia Treatment (Hair Loss) Market

Alopecia areata is a medical condition which is a type of alopecia which attacks the hair follicles causes the breakage or fall of hair leading to complete baldness. The patient suffering from alopecia areata their scalp becomes patchy, diffused and confluent pattern leading the hair fall initially and later spread over the entire scalp termed as alopecia totalis or entire epidermis.

Alopecia areata is an auto immune hair loss on scalp or on body and commonly it shows form of solitary and multiple patches of alopecia.

Market Drivers:

  • Rising geriatric population along with high demand for surgical hair transplant will boost the market
  • Changing lifestyle along with increase in stress level among working class population can fuel the growth of the market

Market Restraints:

  • High cost of alopecia treatment (hair loss) is acting as a major restraint for the market
  • Side effects/allergic reactions by treatment also acting as a major market restraint.

Segmentation: Global Alopecia Treatment (Hair Loss) Market

  • By Disease Type
    • Androgenic Alopecia
    • Alopecia Areata
    • Ciatricial Alopecia
    • Traction Alopecia
    • Alopecia Totalis
  • By Drug Type
    • Minoxidil
    • Finasteride
    • Cyclosporine
    • Others
  • By Gender
    • Male
    • Female
  • By Route of Administration
  • Oral
    • Topical
    • Injectable
  • By Distribution Channel
    • Hospital
    • Retail Pharmacies
    • Online Pharmacies
  • By Geography
    • North America
      • US
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Malaysia
      • Indonesia
      • Thailand
      • Philippines
      • Rest of Asia-Pacific
    • Middle East and Africa
      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of the Middle East and Africa

Key Developments in the Market:

  • In January 2018, Concert Pharmaceuticals, Inc. announced U.S. FDA granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, a disease which attacks the hair follicles, leading to hair loss.
  • In May 2018, Histogen, Inc (U.S.) announced that received approval to Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to study its lead product in female diffuse hair loss.
  • In March 2017, Perrigo Perrigo Company PLC (U.S.) announced the launch of over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Competitive Analysis: Global Alopecia Treatment (Hair Loss) Market

The global alopecia treatment (hair loss) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of alopecia treatment (hair loss) market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Alopecia Treatment (Hair Loss) Market

Few of the major market competitors currently working in the alopecia treatment (hair loss) market are Cipla, Viviscal, Dr Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr Kurt Wolff GmbH & Co. KG, Rogaine – Johnson and Johnson, Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Perrigo Company PLC. and Daiichi Sankyo, Inc.

Research Methodology: Global Alopecia Treatment (Hair Loss) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:

  • Current and future of global alopecia treatment (hair loss) market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds the highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at the country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

Source

Previous Posts

PRP Workshop To Enhance Hair Restoration

Platelet Rich Plasma Alopecia Therapies

Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Analysis 2020-2026 by Size

Kenneth Research offers a comprehensive analysis of key market trends in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. It also includes discussion on historical trends, current market status, competitive landscape, growth opportunities and challenges which are backed by factful feedbacks.

The report extensively provides the quantitative analysis of the industry from 2014-2026, by Region, Type, Application. Consumption assessment by application, production by type in different regions.

Furthermore, the report quantifies the market share held by the major players of the industry and provides an in-depth view of the competitive landscape. The market size in terms of revenue (USD) and production is calculated for the study period along with the details of the factors affecting the market growth (drivers and restraints).

The worldwide market for Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesmarket will reach xxx Million USD in 2020 and is expected to grow at a CAGR of xx% 2021-2026.

Geographically, global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Orange County Hair Restoration Center
Colorado Surgical Center& Hair Institute
Evolution Hair Loss Institute
Hair Sciences Center of Colorado
Hair Transplant Institute of Miami
Anderson Center for Hair
Virginia Surgical Center
Savola Aesthetic Dermatology Center

On the basis of product, we research the production, revenue, price, market share and growth rate, primarily split into

Platelet Rich Plasma Injections
Stem Cell Therapy

For the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia

Therapies for each application, including
Dermatology Clinics
Hospitals

Production, consumption, revenue, market share and growth rate are the key targets for Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies from 2014 to 2026 (forecast) in these regions

China
USA
Europe
Japan
Korea
India
Southeast Asia
South America

Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Analysis 2020-2026 by Size

Source

Previous Posts

CTP-543 Phase 3 Trials in Alopecia Areata

CTP-543 Phase 3 Trials in Alopecia Areata

Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

Concert Pharmaceuticals, Inc today announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Concert discussed key aspects of its planned Phase 3 trials in adult patients with the U.S. Food and Drug Administration (FDA) at a recently conducted End-of-Phase 2 meeting. The Phase 3 program is intended to support filing of a New Drug Application for CTP-543.

“The planned initiation of the Phase 3 program, combined with the positive results of the Phase 2 dose ranging trial, show the continued momentum for our development of CTP-543 for patients with alopecia areata,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “Our Phase 3 clinical program is designed to confirm the previous findings observed with CTP-543 and advance our goal to bring an important new treatment option to people living with this life-altering autoimmune disease. Our intent is to initiate the Phase 3 program in the fourth quarter of 2020, pending COVID-19.”

The planned Phase 3 program for CTP-543 will include two randomized, double-blind, placebo-controlled clinical trials in adults at sites in the U.S., Canada and Europe. The Phase 3 program will evaluate the Severity of Alopecia Tool (SALT) score after 24 weeks of dosing in patients with moderate-to-severe alopecia areata. Key aspects of the Phase 3 trials include:

  • Patients age 18-65 years with ≥ 50% hair loss;
  • Approximately 700 patients are expected to enroll in each of the two Phase 3 trials;
  • Dosing: 8 mg twice-daily or 12 mg twice-daily of CTP-543 or placebo for 24 weeks; and
  • Primary endpoint: Percent of patients achieving a SALT score ≤20 at Week 24.

The End-of-Phase 2 meeting with the FDA was requested as a result of positive data from the dose-ranging Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. Patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks using SALT.

The 8 mg twice-daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving ≥ 75% and ≥ 90% relative change in SALT from baseline at 24 weeks. At Week 24, patients treated with 8 mg twice-daily and 12 mg twice-daily compared to placebo also rated significantly greater improvement in their alopecia areata on the Patient Global Impression of Improvement Scale. Treatment with CTP-543 was generally well tolerated, with one serious adverse event reported in the 12 mg dose group where the patient was able to complete the trial after a brief dose interruption.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

Source

Previous Posts

 

Alopecia Treatment Market

Alopecia Market Business Opportunities 2026

Alopecia Market Business Opportunities 2026

A new research study has been presented by UpMarketResearch.com offering a comprehensive analysis on the Global Alopecia (Hair Loss Treatment) Market where user can benefit from the complete market research report with all the required useful information about this market.

The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

 

The Alopecia (Hair Loss Treatment) Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Alopecia (Hair Loss Treatment) Market Report with Latest Industry Trends @ https://www.upmarketresearch.com/home/requested_sample/105857

Major Players Covered in this Report are:

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter & Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Global Alopecia (Hair Loss Treatment) Market Segmentation

This market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level.

Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:

Shampoos and Conditioners
Medicine Product

By Applications:

Men
Women

Global Alopecia (Hair Loss Treatment) Market Regions and Countries Level Analysis

 

Regional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Alopecia (Hair Loss Treatment) on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Alopecia (Hair Loss Treatment) sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted.

This study provides Alopecia (Hair Loss Treatment) sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Alopecia Market Business Opportunities 2026

Source

Previous Posts

 

Alopecia Treatment Market

Alopecia Treatment Market Growth

Alopecia Treatment Market Growth and Forecast Report, 2020 – 2026

The Global Alopecia Treatment Market research report provides all-inclusive industry research with the latest and astoundingly affirmed sectors. This report covers all the consumption trends and the prominent players with market size, share, growth for the forecast period from 2020-2026.

The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the alopecia treatment market include Capillus, Cipla, Inc., Cirrus Hair Centers, Follica, Inc., Johnson & Johnson Services, Inc., Lexington Intl., LLC, Merck & Co., Inc, Sun Pharmaceuticals Industries Ltd., Transitions Hair, Vita-Cos-Med Klett-Loch GmbH, and others. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.

Market Dynamics

The rising cases of hair loss because of chronic disorders and stress coupled with the advancement in the hair loss treatment are the prominent factors propelling the market growth. Rising disposable income and growing sense of aesthetic appeal are further expected to fuel the market demand. Moreover, the rising number of geriatric population and growing awareness regarding hair loss treatment is also projected to increase the market value. However, the high cost of the treatment is likely to impede market growth.

This detailed market study is centred on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights into the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of alopecia treatment.

Market Segmentation

The broad alopecia treatment market has been sub-grouped into type, end-use, sales channel, and gender. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target a specific market. This detail will lead to a focused approach leading to identification of better opportunities.

By Type

Alopecia Areata
Cicatricial Alopecia
Traction Alopecia
Alopecia Totalis
Alopecia Universalis
Androgenetic Alopecia
Others

By End-Use

Dermatology Clinics
Homecare Setting

By Sales Channel

Prescription
OTC

By Gender

Male
Female

Regional Analysis

Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for alopecia treatment in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.

Alopecia Treatment Market Growth and Forecast Report, 2020 – 2026

Source

Previous Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

Open Label Trial of CTP-543 in Patients with Alopecia Areata

Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata

Concert Pharmaceuticals, Inc. today announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata. Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily results from the Company’s Phase 2 trial of CTP-543. Treatment was generally well tolerated in both arms of the study. All but one of the patients who completed this trial have elected to continue in an open-label long-term extension study. The Company expects to report findings from the study at a future medical meeting

“Based on the results observed, the twice-daily regimen is preferred, and we intend to utilize it in our clinical development program for CTP-543 going forward,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “We believe that the findings from our dose regimen studies may be valuable to CTP-543’s intellectual property portfolio and therefore are not disclosing additional data from this study at this time.”

The dose regimen trial (NCT03811912) was a randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice-daily oral dosing of CTP-543, in adult patients with moderate-to-severe alopecia areata. Fifty-seven patients in the trial were randomized to receive CTP-543 either 8 mg twice-daily or 16 mg once-daily over a 24-week treatment period. The trial measured the relative change in Severity of Alopecia Tool (SALT) score between Week 24 and baseline.

Data from the Company’s Phase 2 trials will support an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to review and discuss the Company’s registration pathway for CTP-543 for the treatment of alopecia areata. The Company expects to meet with the FDA and initiate Phase 3 testing in 2020.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata

Source

Previous Posts

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for Alopecia

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for Alopecia

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution

Cassiopea SpA, a specialty pharmaceutical company focused on developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today that it has received approval from the German Authority BfArM and the coordinating ethical committee and will now proceed to enroll the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in females.

The Phase II multicenter, prospective, randomized, double-blind, vehicle controlled, dose ranging study will evaluate the efficacy and safety of clascoterone solution for the treatment of AGA in females. The six-month study will enroll approximately 280 female subjects between 18-55 years of age with mild to moderate AGA in Germany.

The four-arm study will enroll 70 subjects per arm in each of four treatment groups: clascoterone solution 5% BID (twice daily), clascoterone solution 7.5% BID (twice daily), minoxidil solution 2% BID (twice daily) and vehicle BID (twice daily). The co-primary endpoints are: (1) change from baseline in non-vellus Target Area Hair Count (TAHC) at month 6 in comparison to vehicle and (2) Hair Growth Assessment (HGA) score at month 6 in comparison to vehicle.

Clascoterone, a new chemical entity, is a proposed first-in-class topical androgen receptor inhibitor currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of acne (in a 1% cream) and in late stage development for the treatment of AGA (in a higher strength solution).

Laboratory studies suggest clascoterone competes with androgens, specifically dihydrotestosterone (DHT), for binding to the androgen receptors within the sebaceous gland and hair follicles. Because of clascoterone’s likely local effect at the site of application, the risk of off-target, or systemic side effects, is minimized.

AGA is a leading cause of hair loss in men and women. In AGA, high local concentrations of DHT bind to androgen receptors within the scalp hair follicles, resulting in shortening of the hair cycle and gradual miniaturization of scalp follicles in men and women with a genetic predisposition.

Over time, these progressively smaller, thinner hair follicles are unable to produce new hair, thus resulting in AGA’s characteristic patterned baldness. DHT dependent effects are considered, in most cases, reversible, such that AGA could be responsive to medical treatment with clascoterone solution through its proposed MOA of direct inhibition of testosterone and DHT binding to local hair follicle androgen receptors. Clascoterone has the potential to be the only topical antiandrogen for use in both men and women with AGA if approved by the FDA.

Based on early clinical review, Cassiopea believes that topical clascoterone will not have the contraindications and safety warnings of an orally administered androgen modulator used for the treatment of AGA in men. It appears Clascoterone does not interfere with the hormonal and, in particular, testosterone profiles of male subjects; libido and sexual behavior changes have not been observed in clinical trials to date. Clascoterone is quickly metabolized to cortexolone, a metabolite with a known safety profile. Due to its rapid metabolism and local activity, there appears to be limited systemic exposure to clascoterone and thus potential systemic side effects are minimized.

On April 16, 2019, Cassiopea announced topline results from the Phase II Dose Ranging trial in males demonstrating statistically significant improvement versus vehicle for TAHC for each dose tested along with directional improvement for HGA at twelve months. No treatment-related serious adverse events among patients were recorded during the trial; local skin reactions, if present, were similar to vehicle and predominantly classified as mild.  Cassiopea has an End of Phase II Meeting with FDA scheduled on November 13, 2019, to discuss the AGA Phase III Program in males with clascoterone solution.

“Clascoterone, a unique topical androgen receptor inhibitor, has shown a remarkable increase in hair growth as compared to vehicle with minimal side effects in the Phase II Dose Ranging Study in males. If FDA approved, it will be a very welcomed and important therapy for female and male patterned hair loss, androgenetic alopecia,” said Wilma Bergfeld, Professor of Dermatology and Pathology at Cleveland Clinic and Past President, American Academy of Dermatology and American Society of Dermatopathology.

“If approved, clascoterone solution will be the first new mechanism of action for the treatment of androgenetic alopecia in decades, offering dermatologists and patients a new and potentially effective therapeutic alternative,” said Diana Harbort, CEO of Cassiopea. “We’re focused on the urgency to treat skin and scalp conditions that can leave not only physical scars, but also emotional scars. That’s why innovation is so critical. We are committed to finding a new pathway to treat the most common form of hair loss affecting both men and women.”

About Cassiopea

Cassiopea is a specialty pharmaceutical company focused on developing and commercializing prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia and genital warts.

Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. If approved, Cassiopea plans to commercialize the products directly in the U.S. and partner the products for countries outside of the U.S. For further information on Cassiopea, please visit www.cassiopea.com.

About Clascoterone

Clascoterone, a new chemical entity, is a proposed first in class topical androgen receptor inhibitor under FDA review for the treatment of acne (in a 1% cream) and in late stage development for androgenetic alopecia (in a higher strength solution). Laboratory studies suggest clascoterone competes with androgens, specifically DHT, for binding to the androgen receptors within the sebaceous gland and hair follicles. When applied directly to the skin surface, clascoterone appears to target only local androgen receptors within the skin.  Because of clascoterone’s likely local effect at the site of application, the risk of off-target, or systemic side effects, is minimized.

Next events  

CS Small & Mid Cap Conference, Zurich
November 13, 2019

Jefferies Health Care Conference, London
November 20, 2019

Full-year results 2019
February 2020

Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution

Source

Previous Posts

PRP Workshop To Enhance Hair Restoration

Platelet Rich Plasma Alopecia Therapies

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size,Status and Forecast 2019-2025

Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery, and preliminary evidence suggests that it might have a beneficial role in hair regrowth.
In 2018, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players.

The study objectives are to present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Orange County Hair Restoration Center
Hair Sciences Center of Colorado
Anderson Center for Hair
Evolution Hair Loss Institute
Savola Aesthetic Dermatology Center
Virginia Surgical Center
Hair Transplant Institute of Miami
Colorado Surgical Center & Hair Institute

Market segment by Type, the product can be split into

Platelet Rich Plasma Injections
Stem Cell Therapy

Market segment by Application, split into

Dermatology Clinics
Hospitals

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players.
To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies are as follows:

History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size,Status and Forecast 2019-2025

Source

Previous Posts

Male Androgenetic Alopecia

Global Alopecia Treatment Market Size

Global Alopecia Treatment Market Size, Status And Forecast 2019-2025

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues.

Changing lifestyle along with increase in stress level among working class population is expected to boost the demand for treatment of hair loss globally. Furthermore, rise in geriatrics population along with high demand for surgical hair transplant is expected to drive the alopecia treatment market.

Increasing consumer disposable incomes and health awareness, emphasis to look good, and technological advancement in hair treatment medical devices are some other key drivers for this market. Since accessibility for scalp treatment is easily accessible and available, the demand for alopecia treatment has increased.

Though the market is expected to witness healthy growth during the forecast period, high cost of the medications and possible side effects/allergic reactions are acting as key barrier for alopecia market.
In 2018, the global Alopecia (Hair Loss)Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Alopecia (Hair Loss)Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Alopecia (Hair Loss)Treatment development in United States, Europe and China.

The key players covered in this study
Cipla
Dr. Reddy’s Laboratories
Regaine
Merck
Ranbaxy Laboratories
Vitabiotics
Nanogen
Alpecin
Johnson and Johnson

Market segment by Type, the product can be split into
Vitamins and Supplements
Shampoos and Conditioners
Others

Market segment by Application, split into
Men
Women
Children

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Alopecia (Hair Loss)Treatment status, future forecast, growth opportunity, key market and key players.
To present the Alopecia (Hair Loss)Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Alopecia (Hair Loss)Treatment are as follows:

History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Alopecia Treatment Market Size, Status And Forecast 2019-2025

Source

Previous Posts